- Name: Qiu Miao-zhen
- Title: Professor
- Email: qiumzh@sysucc.org.cn
- Phone:
Profile
Principal Investigator (PI) at the National Key Laboratory for Prevention and Treatment of Malignant Tumors in South China;
Project Leader of a Major National Science and Technology Project on Four Major Chronic Diseases;
National High-Level Young Talent recognized by the Ministry of Education;
Recipient of the Guangdong Natural Science Fund for Distinguished Young Scholars;
Awarded five national and provincial-level honors, including the Second Prize of the National Science and Technology Progress Award and the First Prize of Provincial/Ministerial Science and Technology Progress Award;
Ranked in the "World's Top 2% Scientists" for annual scientific impact in 2024/2025;
Recipient of the ESMO Merit Award and research grants from the US-China Anti-Cancer Association and the Asian Cancer Research Foundation;
Serves as a member of the CSCO Gastric Cancer Expert Committee and a contributing author to the CSCO Gastric Cancer Guidelines;
Has published over 90 SCI papers as first or corresponding author in journals such as BMJ, Nature Medicine, JAMA Oncology, and Signal Transduction and Targeted Therapy, with an H-index of 48.
Interests
Chemotherapy, target therapy andimmunotherapy for gastrointestinal tumors,Clinical research on new drugs.
Education
September 2001 - June 2006:Sun Yat-sen University Zhongshan School of Medicine,Clinical Medicine (Seven-year Program)
August 2006 - June 2008:Sun Yat-sen University Cancer Center,Department of Medical Oncology,Master's Student (Seven-year Program)
September 2012 - June 2015:Sun Yat-sen University Cancer Center,Oncology
Doctoraldegree.
Publications
1. Dan-Yun Ruan# , Hao-Xiang Wu#, Su-Xia Luo#, Wen-Wen Huang#, Xin-Jun Liang, Zuo-Xing Niu, Qi Dang, Hong-Li Li, Zhan-Yu Pan, Hong-Xia Lu, Yan-Qiao Zhang, Xing-Ya Li, Xiu-Ying Xiao, Shi-Rong Cai, Yu-Gang Dong, Jian Zhang, Zhou Li, Hai-Tao Lan, Xin Wang, Ying Zhou, Lian Liu, He-Li Liu, Ping-Sheng Xu, Ai-Li Suo, Rui-Nuo Jia, Yong-Qiang Li, Xiao-Dong Peng, Si-Chen Wang, Ai-Ai Yu, Jie Xie, Miao-Zhen Qiu*, Rui-Hua Xu* .The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial. Nature Medicine.2025 Sep;31(9):3037-3046.(Co-corresponding author);
2. Miao-Zhen Qiu#,Do-Youn Oh, Ken Kato, Tobias Arkenau, Josep Tabernero, Marcia Cruz Correa, Anastasia V Zimina, Yuxian Bai, Jianhua Shi, Keun-Wook Lee, Jufeng Wang , Elena Poddubskaya, Hongming Pan, Sun Young Rha, Ruixing Zhang, Hidekazu Hirano, David Spigel, Kensei Yamaguchi, Yee Chao, Lucjan Wyrwicz, Umut Disel, Roberto Pazo Cid, Lorenzo Fornaro, Ludovic Evesque, Hongwei Wang, Yaling Xu, Jiang Li, Tao Sheng, Silu Yang, Liyun Li, Markus Moehler, Rui-Hua Xu*. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.BMJ.2024 May 28.385:e078876.( First author);
3. Miao-Zhen Qiu#*, Yuxian Bai, Jufeng Wang, Kangsheng Gu, Mudan Yang, Yifu He, Cheng Yi, Yongdong Jin, Bo Liu, Feng Wang, Yu-Kun Chen, Wei Dai, Yingyi Jiang, Chuanpei Huang, Rui-Hua Xu*, Hui-Yan Luo*. Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer.Signal Transduct Target Ther.2024 Dec 16;9(1):349.(First & co-corresponding author);
4. Miao-Zhen Qiu#, Chaoye Wang#, Zhiying Wu#, Qi Zhao#, Zhibin Zhao#, Chun-Yu Huang, Wenwei Wu, Li-Qiong Yang, Zhi-Wei Zhou, Yu Zheng, Hong-Ming Pan, Zexian Liu, Zhao-Lei Zeng, Hui-Yan Luo, Feng Wang, Feng-Hua Wang, Si-Yu Yang, Meng-Xing Huang, Zhexiong Lian, Haiyan Zhang* & Rui-Hua Xu*. Dynamic single-cell mapping unveils Epstein‒Barr virus imprinted T-cell exhaustion and on-treatment response.Signal Transduct Target Ther.2023 Sep 21;8(1):370.( First author);
5. Jin-Fei Lin#, Pei-Shan Hu,# Yi-Yu Wang#, Yue-Tao Tan#, Kai Yu, Kun Liao, Qi-Nian Wu, Ting Li, Qi Meng, Jun-Zhong Lin, Ze-Xian Liu, Heng-Ying Pu, Huai-Qiang Ju*, Rui-Hua Xu* & Miao-Zhen Qiu* .Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis. Signal Transduct Target Ther.2022 Feb 28;7(1):54.(Last corresponding author);
6. Miao-Zhen Qiu#, Yang Zhang# , Ye Guo, Wei Guo , Weiqi Nian, Wangjun Liao , Zhongyuan Xu, Wenxue Zhang, Hong-Yun Zhao, Xiaoli Wei, Liqiong Xue, Wenbo Tang, Yunteng Wu , Guoxin Ren, Ling Wang, Jingle Xi, Yongshuai Jin, Hu Li , Chaohong Hu , Rui-Hua Xu*.Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial.JAMA Oncology.2022 Jul 1;8(7):1042-1046.( First author);
7. Zhen Zhang#, Zi-Xian Wang#, Yan-Xing Chen#, Hao-Xiang Wu # , Ling Yin, Qi Zhao, Hui-Yan Luo, Zhao-Lei Zeng, Miao-Zhen Qiu*, Rui-Hua Xu*.Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response.Genome Medicine.2022 Apr 29;14(1):45.(Co-corresponding author);
8. Yang Zhang# ,Miao-Zhen Qiu#, Ju-Feng Wang , Yan-Qiao Zhang , Ao Shen , Xiang-Lin Yuan , Tao Zhang, Xiao-Li Wei, Hong-Yun Zhao, De-Shen Wang, Qi Zhao , Gao-Zhun Xiong , Yan-Ping Ji , Xue-Jun Liang , Gang Xia , Rui-Hua Xu*.Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma.Cell Reports Medicine.2022 Nov 15;3(11):100814.(Co-first second author);
9. Ze-Xian Liu#, Xiao-Long Zhang#, Qi Zhao# , Yungchang Chen , Hui Sheng , Cai-Yun He , Yu-Ting Sun , Ming-Yu Lai, Min-Qing Wu, Zhi-Xiang Zuo, Wei Wang, Zhi-Wei Zhou, Feng-Hua Wang, Yu-Hong Li, Rui-Hua Xu*, Miao-Zhen Qiu*.Whole-Exome Sequencing Among Chinese Patients With Hereditary Diffuse Gastric Cancer.JAMA Network Open.2022 Dec 1;5(12):e2245836.(Last corresponding author);
10. F-R Liu#, X-L Wei#, W-N Feng, H-Y Zhao, Y Zhang, Z-Q Wang, D-S Zhang, F-H Wang , S Yang, W Pan, X Tian, L Men, H Wang, E Liang, C Wang, D Yang, Y Zhai*, M-Z Qiu* , R-H Xu*. Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab in patients with advanced solid tumors: results from two phase I trials.ESMO Open.2024 Aug;9(8):103651.(Co-corresponding author);